ZIM reports 17 EU/UK pipeline products and six approvals

Zeal & Innovation in Medicine (ZIM) reports 17 innovative-product and oral-thin-film candidates in its European Union (EU) and United Kingdom (UK) pipeline, including six stated regulatory approvals. The portfolio comprises 12 NIP candidates and five OTF candidates, while ZIM allocated Rs 4.5 crore in Q2 FY27 to bioequivalence studies and registrations.

What is ZIM's EU/UK product pipeline?

ZIM's EU/UK pipeline comprises 12 NIP products in active development across seven therapy areas and five OTF products across three therapy areas, for 17 candidates in total. The NIP slide states that three regulatory approvals have been secured and several products are ready for filing, while the OTF slide also states three approvals.

NIP represents 12 of the 17 disclosed candidates, compared with five OTF candidates. Both platforms report three approvals despite the difference in portfolio size. ZIM does not provide expected approval dates, launch dates or sales forecasts for individual EU/UK products.

ZIM says some pipeline products have been commercialised in rest-of-world markets, including India, on a business-to-business basis. The presentation does not identify the products involved, the markets served or revenue from those commercialised products.

Which therapies and named products does ZIM list?

ZIM lists NIP candidates in urology, gastrointestinal conditions, anti-coagulants, central nervous system (CNS) conditions, rheumatoid arthritis, anti-infectives, analgesics and anti-psoriatic skin disorders. The named NIP products are Dabigatran Etexilate, Di-Methyl Fumarate and Azithromycin suspension; the other nine entries are labelled as numbered products.

The NIP table contains three urology entries and three gastrointestinal entries, with one entry in each of the other six displayed therapy descriptions. Although the slide headline states seven therapy areas, the table displays eight distinct labels, and ZIM does not explain the difference.

ZIM's five OTF candidates span CNS, erectile dysfunction and opioid de-addiction. Rizatriptan is listed in CNS, Sildenafil in erectile dysfunction and Buprenorphine in opioid de-addiction, while two entries are numbered products. The table contains two CNS entries, two erectile-dysfunction entries and one opioid-de-addiction entry.

What is ZIM's approval and filing position?

ZIM states that it has three NIP approvals and three OTF approvals, while three NIP products are at end of process in the EU. The company says the three NIP products await EU good manufacturing practice (EU-GMP) certification to complete the marketing-authorisation process.

The NIP approval marks are shown against Dabigatran Etexilate, Di-Methyl Fumarate and Azithromycin suspension. The OTF table shows approval marks for Rizatriptan and Buprenorphine, although its headline states that three OTF approvals are secured. ZIM does not name the third approved OTF product or provide approval dates and jurisdictions.

The presentation's development framework covers market review, formulation development, validation, bioequivalence (BE) studies, regulatory filing, approval and commercial supplies. It says several NIP products are ready for filing, but gives no filing timetable. For the three NIP products at EU end of process, EU-GMP certification is the stated remaining condition.

How much is ZIM investing in pipeline development?

ZIM allocated Rs 4.5 crore in Q2 FY27 to BE studies and registrations supporting the NIP and OTF pipeline, within a total research and development (R&D) allocation of Rs 9.9 crore. The total allocation covered product development, dossier upgrades, registrations and infrastructure.

ZIM reported an R&D team of 114 people, including 95 post-graduates and two PhDs. This includes 27 regulatory-affairs employees; excluding them, net R&D headcount was 87, including 75 post-graduates and two PhDs. The company also reported eight NIP filings in the EU to date and four versatile technology platforms.

R&D investment was 9.1% of operating income in H1 FY27, compared with 9.7% in H1 FY26. Capital expenditure on BE studies and registration rose to 44% of the R&D mix from 29%, while research and development expenses recognised in the profit and loss account declined to 55% from 70%; infrastructure and equipment remained at 1% in both periods.

How does the pipeline relate to ZIM's revenue mix?

ZIM's innovative-product revenue, defined as NIP plus OTF, increased 84% year on year to Rs 14.9 crore in Q2 FY27 and accounted for 14% of total operating income, versus 9% a year earlier. Including dossier-licensing fees, innovative products represented 16% of Q2 FY27 operating income.

For H1 FY27, innovative-product contribution including licensing income was Rs 33.7 crore, compared with Rs 20.1 crore in H1 FY26, a 68% increase. The presentation does not split this contribution between NIP, OTF, dossier licensing, EU/UK candidates or products commercialised in rest-of-world markets.

Pharmaceutical revenue was Rs 83 crore in Q2 FY27 and represented 79% of total revenue, while nutraceutical revenue was Rs 22.5 crore and represented 21%. Export revenue reached Rs 90.8 crore, or 86% of revenue, rising 24.7% year on year. ZIM does not state how much pharmaceutical or export revenue came from innovative products.

Conclusion

ZIM's disclosed EU/UK pipeline combines 12 NIP candidates and five OTF candidates, with six approvals stated across the two platforms. Its development spending and revenue disclosures provide context: Rs 4.5 crore was allocated to BE studies and registrations in Q2 FY27, while NIP and OTF revenue reached Rs 14.9 crore.

The next disclosed regulatory milestone is completion of marketing authorisation for three EU NIP products awaiting EU-GMP certification. ZIM also says several NIP products are ready for filing, so subsequent filings, approval disclosures and clarification of the third OTF approval are matters to watch.